marimastat has been researched along with Body Weight in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, M; Igarashi, N; Kameyama, K; Kimata, M; Kitajima, M; Kubota, T; Kumai, K; Okada, Y; Otani, Y; Wada, N; Yokoyama, T; Yoshimizu, N | 1 |
| Alwayn, IP; Arsenault, DA; Greene, AK; Kim, S; Laforme, A; Lee, S; Moses, MA; Novak, K; Puder, M; Roy, R; Verbesey, JE | 1 |
2 other study(ies) available for marimastat and Body Weight
| Article | Year |
|---|---|
Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Body Weight; Cell Survival; Coloring Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Hydroxamic Acids; Male; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred BALB C; Mice, Nude; Mitomycin; Models, Chemical; Neoplasm Metastasis; Neoplasm Transplantation; Peritoneum; Stomach Neoplasms; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured | 2002 |
A critical role for matrix metalloproteinases in liver regeneration.
Topics: Animals; Body Weight; Enzyme Inhibitors; Hepatectomy; Hepatocyte Growth Factor; Hydroxamic Acids; Interleukin-6; Liver; Liver Function Tests; Liver Regeneration; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C57BL; Microcirculation; Organ Size; Receptors, Tumor Necrosis Factor, Type II; Tumor Necrosis Factor-alpha | 2008 |